Buprenorphine, Urine Screen with Reflex to Quantitation
Also known as: BUPR RFX U
Use
This test is useful for general screening in contexts of compliance and/or abuse. The screen with reflex testing is the preferred method for ruling out buprenorphine exposure. If a specimen screens positive, it undergoes confirmation and quantitation testing by liquid chromatography-tandem mass spectrometry, which provides specific identification and quantification of buprenorphine and its metabolites.
Special Instructions
The presence of metabolites without the parent drug is common and may indicate recent use. If the screen is positive, reflex testing with additional charges applies. For medical purposes only; not valid for forensic use.
Limitations
Presumptive results may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or diluted/adulterated urine. The concentration at which the screening test detects a drug or metabolite varies within a drug class. Limitations of testing may result in false negatives or positives.
New York Approved
Methodology
Immunoassay
Biomarkers
LOINC Codes
- 54247-2
- 93494-3
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
4 mL
Minimum Volume
2 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Transfer 4 mL urine with no additives or preservatives to an ARUP Standard Transport Tube (Min: 2 mL).
Storage Instructions
Room temperature.
Causes for Rejection
Unknown fluids, pharmaceutical preparations, and breast milk. Specimens exposed to repeated freeze/thaw cycles.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 1 month |
| Frozen | 1 month |